Various authors have found a higher level of CCL5 in serum and CSF for both the MS groups and the patients with no symptoms of inflammatory–non-inflammatory neurological disease (NIND) during a relapse in MS [4,7,8,9]. The gene discussed is CCL5; the disease is myeloid sarcoma.